Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Preclinical evidence supporting dual inhibition of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP) as an epigenetic strategy for treating prostate cancer is mounting.

In a paper published in Cancer Research, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported development of a small molecule p300/CBP bromodomain inhibitor, GNE-049, that blocked expression of key proliferative genes and reduced tumor growth in mouse models of prostate cancer...